The acquisition closed on September 23, 2026 (SEC 8-K 2.01). Its last closing price was on September 23, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from September 23, 2026. Source: SEC 8-K 2.01
Theravance Biopharma, Inc. TBPH
NasdaqSmall CapHealthcare
Final 13F Pro quality score
Final rank #281 of 2,968 · as of September 23, 2026TOP 10%
AI-extracted from the 10-Q filed 2026-08-11 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Theravance reported Q2 FY2026 revenue of $20.7M (-21% YoY) as it agreed to be acquired by Zymeworks for $17.00/share cash plus a CVR, while winding down its failed ampreloxetine program.
Biggest Revenue Drivers
Viatris collaboration agreement$20.7M+11% YoY
Higher YUPELRI net sales, which grew 7% YoY driven by 10% customer demand growth
Licensing and milestone revenue$0-100% YoY (NM)
Prior-year quarter included a one-time $7.5M milestone from YUPELRI's China NMPA approval; no milestone this quarter
Biggest Revenue Drivers
Total revenue: $20.7M-21% YoY
Viatris collaboration agreement$20.7M+11% YoY
Higher YUPELRI net sales, which grew 7% YoY driven by 10% customer demand growth
Licensing and milestone revenue$0-100% YoY (NM)
Prior-year quarter included a one-time $7.5M milestone from YUPELRI's China NMPA approval; no milestone this quarter
Largest Expense Items
Selling, general and administrative$14.2M-23% YoY
Cost savings from the Restructuring and lower pre-commercial CYPRESS launch spend
Transaction-related expenses$6.1MNM (vs. $0 PY)
Legal and financial advisory costs related to the Zymeworks Merger Agreement
Research and development$4.7M-55% YoY
Lower employee-related and external costs from the Restructuring and CYPRESS wind-down
Restructuring expenses$4.0MNM (vs. $0 PY)
One-time severance and equity-award modification costs from the March 2026 workforce reduction
Margins: No gross margin is presented; R&D and SG&A fell 55% and 23% YoY on Restructuring savings, but new Restructuring and Merger transaction costs widened the operating loss to $8.3M from $2.7M a year ago.
Watch Items from the Filing
Theravance agreed to be acquired by Zymeworks for $17.00/share cash plus a contingent value right; close expected H2 2026, subject to shareholder and regulatory approval.
Ampreloxetine's Phase 3 CYPRESS study missed its primary endpoint in March 2026, triggering a wind-down and ~50% reduction of the 90-employee workforce.
Total revenue is entirely dependent on the single Viatris/YUPELRI collaboration, with no other commercial products contributing.
A $32.5M termination fee is payable to Zymeworks if the Merger Agreement is terminated under specified circumstances.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARYDisposition to issuer · Sep 23, 2026
Congress trading in TBPH
1 transaction in TBPH reported by 1 member of Congress under the STOCK Act, most recent trade Mar 24, 2025. Reported transactions, not recommendations.
About Theravance Biopharma, Inc. (TBPH): stock profile, AI score and financials
Acquired by Zymeworks Inc.: Theravance Biopharma, Inc. (TBPH) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on September 23, 2026 (SEC 8-K 2.01). Its last closing price was on September 23, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from September 23, 2026. Theravance Biopharma, Inc. (TBPH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks TBPH using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q2 2026), Theravance Biopharma, Inc. reports quarterly revenue of $20.7M, net income of $-5.9M, an operating margin of -39.9%. Top institutional holders of TBPH by reported 13-F value include Madison Avenue Partners, Weiss Asset Management, BlackRock, based on the most recent SEC filings. TBPH trades on the Nasdaq exchange and files with the SEC under CIK 1583107. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TBPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theravance Biopharma, Inc. directly from SEC EDGAR.